Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effects of Standardized Brazilian Green Propolis Extract (EPP-AF®) on Inflammation in Haemodialysis Patients: A Clinical Trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Hindawi Country of Publication: United States NLM ID: 101546753 Publication Model: eCollection Cited Medium: Print ISSN: 2090-214X (Print) NLM ISO Abbreviation: Int J Nephrol Subsets: PubMed not MEDLINE
    • بيانات النشر:
      Publication: 2011- : New York : Hindawi
      Original Publication: London : SAGE-Hindawi Access to Research
    • نبذة مختصرة :
      Background: Patients on haemodialysis (HD) present a significant inflammatory status, which has a pronounced negative impact on their outcomes. Propolis is a natural resin with anti-inflammatory and immunomodulatory properties. We assessed the safety and impact of a standardized Brazilian green propolis extract (EPP-AF®) on the inflammatory status in patients under conventional HD.
      Methods: Patients were assigned to receive 200 mg/day of EPP-AF® for 4 weeks followed by 4 weeks without the drug, and changes in plasma levels of interleukins (ILs), interferon gamma (IFN- γ ), tumour necrosis factor-alpha (TNF- α ), and high-sensitivityc-reactive protein (HsCRP) were measured. A heatmap was used to illustrate trends in data variation.
      Results: In total, 37 patients were included in the final analysis. Patients presented an exacerbated inflammatory state at baseline. During EPP-AF® use, there was a significant reduction in IFN- γ ( p =0.005), IL-13 ( p =0.04 2), IL-17 ( p =0.039), IL-1ra ( p =0.008), IL-8 ( p =0.009), and TNF- α ( p   <  0.001) levels compared to baseline, and significant changes were found in Hs-CRP levels. The heatmap demonstrated a pattern of pronounced proinflammatory status at baseline, especially in patients with primary glomerulopathies, and a clear reduction in this pattern during the use of EPP-AF®. There was a tendency to maintain this reduction after suspension of EPP-AF®. No significant side effects were observed.
      Conclusion: Patients under haemodialysis presented a pronounced inflammatory status, and EPP-AF® was demonstrated to be safe and associated with a significant and maintained reduction in proinflammatory cytokines in this population. This trial is registered with Clinicaltrials.gov NCT04072341.
      Competing Interests: Dr. Berretta is an employee of Apis Flora. Dr. Silveira and all the other authors, except for Dr. Teles, Dr. Berretta, Dr. Borges, Dr. Santos, and Dr. Silva, are employed by São Rafael Hospital, which is a part of the D'Or Institute for Research and Education.
      (Copyright © 2022 Marcelo Augusto Duarte Silveira et al.)
    • References:
      Biomed Pharmacother. 2020 Nov;131:110622. (PMID: 32890967)
      Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii28-iii34. (PMID: 30281132)
      Kidney Int. 1999 May;55(5):1899-911. (PMID: 10231453)
      Int J Artif Organs. 2016 Nov 10;39(9):479-486. (PMID: 27834446)
      Kidney Int Suppl. 2000 Aug;76:S104-11. (PMID: 10936806)
      J Ethnopharmacol. 2019 Dec 5;245:112174. (PMID: 31442620)
      Kidney Int. 1999 Feb;55(2):648-58. (PMID: 9987089)
      Kidney Int Rep. 2021 Jul 06;6(9):2358-2370. (PMID: 34514197)
      Nephrol Dial Transplant. 2019 May 1;34(5):870-877. (PMID: 30307514)
      Toxins (Basel). 2017 Mar 23;9(4):. (PMID: 28333114)
      J Exp Psychol Gen. 2012 Feb;141(1):2-18. (PMID: 21823805)
      Nephrol Dial Transplant. 2014 Feb;29(2):414-22. (PMID: 24235073)
      Toxins (Basel). 2021 Feb 13;13(2):. (PMID: 33668632)
      BMC Nephrol. 2019 Apr 25;20(1):140. (PMID: 31023272)
      Biomed Pharmacother. 2021 Jun;138:111526. (PMID: 34311528)
      Sci Rep. 2021 Mar 15;11(1):5925. (PMID: 33723330)
      Nephrol Dial Transplant. 2009 Feb;24(2):562-70. (PMID: 18809977)
      Hum Immunol. 2022 Feb;83(2):134-143. (PMID: 34802797)
      Eur J Clin Invest. 2015 Dec;45(12):1333-40. (PMID: 26519693)
      Kidney Int. 1998 Jul;54(1):236-44. (PMID: 9648084)
      J Pharm Pharmacol. 2021 Mar 4;73(2):135-144. (PMID: 33793799)
      Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii35-iii40. (PMID: 30281126)
      Int J Biol Sci. 2012;8(4):512-21. (PMID: 22457606)
      Evid Based Complement Alternat Med. 2013;2013:418508. (PMID: 23690844)
      Evid Based Complement Alternat Med. 2013;2013:976415. (PMID: 23840273)
      Kidney Int. 2010 Mar;77(6):550-6. (PMID: 20016471)
      Kidney Int. 1999 Oct;56(4):1571-7. (PMID: 10504510)
      Evid Based Complement Alternat Med. 2013;2013:670451. (PMID: 23710228)
      Contrib Nephrol. 2017;191:1-7. (PMID: 28910786)
      ScientificWorldJournal. 2014 Jan 16;2014:593170. (PMID: 24558316)
      PLoS One. 2015 Jan 21;10(1):e0116535. (PMID: 25607548)
      N Engl J Med. 2002 Nov 14;347(20):1557-65. (PMID: 12432042)
      Lancet. 2017 Oct 21;390(10105):1888-1917. (PMID: 28434650)
    • Molecular Sequence:
      ClinicalTrials.gov NCT04072341
    • الموضوع:
      Date Created: 20221202 Latest Revision: 20221203
    • الموضوع:
      20240628
    • الرقم المعرف:
      PMC9708369
    • الرقم المعرف:
      10.1155/2022/1035475
    • الرقم المعرف:
      36457860